2025-05-29-Jefferies-因特里亚（NTLA）_8-K披露中的三期临床细节；所有项目时间表保持正常_8页_123kb

Intellia Therapeutics (NTLA) released an 8-K disclosing Ph.III study details for itsATTR-CM program. A single case of Gr4 LFT elevation was reported but is mild and resolving, with no changes to study protocols. Enrollment is on track, with 365 patients enrolled and plans to reach 550 by year-end. Analysts maintain a "Buy" rating amid positive progression for future filings.